- Stocks
- Pharma & Healthcare
- Sun Pharmaceutical Industries
Sun Pharmaceutical Industries share price
NSE: SUNPHARMAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Sun Pharmaceutical Industries at a glance
Sun Pharmaceutical Industries (NSE: SUNPHARMA) closed at ₹1,744.40 on 22 Oct 2026, up 0.33% on the day. With a market capitalisation of ₹4,18,540 Cr, it ranks 13th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 36.5× trailing earnings, against a return on equity of 13.7% in FY26. Over the past year the share price has risen 5.6%. Its 52-week range is ₹1,583.70 (29 Jan 2026) to ₹2,046.90 (31 Jul 2026); the last close is 14.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹15,184 Cr (+10.1% year on year) and net profit ₹2,911 Cr (+26.4%), on a consolidated basis. Promoters held 54.48% of the company as of 30 Jun 2026; 1.65% of promoter shares were pledged.
Key numbers
- Market cap
- ₹4,18,540 CrRank 13 on NSE
- P/E (trailing)
- 36.5×
- Price to book
- 5.05×FY26
- EPS (TTM)
- ₹50.40to Q1 FY27
- ROE
- 13.7%FY26
- ROCE
- 19.5%FY26
- Debt to equity
- 0.05FY26
- Net profit margin
- 12.6%FY26
- Book value / share
- ₹348.31FY26
- Dividend payout
- 27.3%FY26
- 52-week high
- ₹2,046.9031 Jul 2026
- 52-week low
- ₹1,583.7029 Jan 2026
- 1-year return
- +5.6%
- RSI (14-day)
- 34
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.33% | +0.2% | −6.7% | −10.3% | +5.6% |
Sun Pharmaceutical Industries quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13,291 Cr | ₹13,437 Cr | ₹12,816 Cr | ₹13,786 Cr | ₹14,405 Cr | ₹15,469 Cr | ₹14,560 Cr | ₹15,184 Cr |
| Revenue YoY | +9.0% | +10.5% | +6.9% | +9.0% | +8.4% | +15.1% | +13.6% | +10.1% |
| Net profit | ₹3,031 Cr | ₹2,918 Cr | ₹2,161 Cr | ₹2,303 Cr | ₹3,137 Cr | ₹3,401 Cr | ₹2,724 Cr | ₹2,911 Cr |
| Net profit YoY | +26.2% | +13.6% | −19.0% | −19.8% | +3.5% | +16.6% | +26.1% | +26.4% |
| Net margin | 22.8% | 21.7% | 16.9% | 16.7% | 21.8% | 22.0% | 18.7% | 19.2% |
| EPS | ₹12.70 | ₹12.10 | ₹9.00 | ₹9.50 | ₹13.00 | ₹14.00 | ₹11.30 | ₹12.10 |
Sun Pharmaceutical Industries financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹33,498 Cr | ₹38,654 Cr | ₹43,886 Cr | ₹48,497 Cr | ₹52,578 Cr | ₹58,462 Cr |
| Operating profit | ₹7,106 Cr | ₹9,048 Cr | ₹9,580 Cr | ₹11,582 Cr | ₹14,430 Cr | ₹16,426 Cr |
| Net profit | ₹2,285 Cr | ₹3,406 Cr | ₹8,561 Cr | ₹9,648 Cr | ₹10,980 Cr | ₹11,565 Cr |
| EPS (₹) | ₹12.00 | ₹14.00 | ₹35.00 | ₹40.00 | ₹46.00 | ₹48.00 |
| Cash from operations | ₹6,170 Cr | ₹8,985 Cr | ₹4,959 Cr | ₹12,135 Cr | ₹14,072 Cr | ₹12,419 Cr |
| Total debt | ₹898 Cr | ₹230 Cr | ₹0 Cr | ₹1 Cr | ₹3 Cr | ₹31 Cr |
| Shareholders' equity | ₹46,463 Cr | ₹48,011 Cr | ₹55,995 Cr | ₹63,667 Cr | ₹72,218 Cr | ₹83,570 Cr |
Sun Pharmaceutical Industries shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| Foreign institutions | 17.96% | 17.26% | 16.55% | 16.12% | 15.93% | 14.53% |
| Domestic institutions | 18.70% | 19.50% | 20.23% | 20.82% | 21.11% | 22.18% |
| Non-institutions | 8.87% | 8.77% | 8.73% | 8.58% | 8.48% | 8.81% |
| Promoter shares pledged | 0.88% | 0.88% | 0.97% | 0.97% | 1.42% | 1.65% |
Sun Pharmaceutical Industries vs peers
The listed Pharma & Healthcare companies nearest to Sun Pharmaceutical Industries by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | ₹1,744.40 | +0.33% | +5.6% | ₹4,18,540 Cr | 36.5 | 13.7% |
| DIVISLABDivi's Laboratories | ₹9,141.00 | +0.46% | +39.5% | ₹2,42,665 Cr | 94.6 | 15.3% |
| TORNTPHARMTorrent Pharmaceuticals | ₹4,604.50 | +1.31% | +30.9% | ₹1,75,140 Cr | 72.1 | 25.8% |
| ZYDUSLIFEZydus Lifesciences | ₹1,123.00 | +0.75% | +14.8% | ₹1,12,020 Cr | 22.4 | 18.6% |
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,569.50 | −0.41% | −2.4% | ₹1,08,838 Cr | 56 | 20.5% |
| LAURUSLABSLaurus Labs | ₹2,010.10 | +0.02% | +129.8% | ₹1,08,596 Cr | 121.7 | 8.0% |
| CIPLACipla | ₹1,312.60 | +0.08% | −15.2% | ₹1,06,038 Cr | 27.3 | 11.3% |
Ask anything about Sun Pharmaceutical Industries
Pivot answers on the live chart with evidence you can check, and tests strategies against SUNPHARMA's own history. Try: “Why has SUNPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SUNPHARMA over five years” · “Compare SUNPHARMA with DIVISLAB on margins and valuation”
Frequently asked questions about Sun Pharmaceutical Industries
What is the share price of Sun Pharmaceutical Industries today?
Sun Pharmaceutical Industries (NSE: SUNPHARMA) last closed at ₹1,744.40 on 22 Oct 2026. Its 52-week high is ₹2,046.90 and its 52-week low is ₹1,583.70.
What is the market cap of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries' market capitalisation is ₹4,18,540 Cr (₹4.19 lakh Cr) at the 22 Oct 2026 close, ranking 13th among the NSE companies Pivot tracks.
What is the P/E ratio of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries trades at a trailing P/E of 36.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 72.1.
What is the ROE and ROCE of Sun Pharmaceutical Industries?
Return on equity was 13.7% in FY26 and return on capital employed was 19.5% in FY26 (consolidated figures).
Is Sun Pharmaceutical Industries a debt-free company?
Sun Pharmaceutical Industries is close to debt-free: its debt-to-equity ratio was 0.05 in FY26.
What were Sun Pharmaceutical Industries' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Sun Pharmaceutical Industries reported revenue of ₹15,184 Cr, +10.1% year on year, and net profit of ₹2,911 Cr, +26.4% year on year.
How has Sun Pharmaceutical Industries stock performed over the last year?
Sun Pharmaceutical Industries' share price has risen 5.6% over the past year, −10.3% over three months and −6.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Sun Pharmaceutical Industries?
As of 30 Jun 2026: promoters 54.48%, foreign institutions 14.53%, domestic institutions 22.18%, non-institutions 8.81%. 1.65% of promoter shares were pledged.
Who are Sun Pharmaceutical Industries' competitors?
The listed Pharma & Healthcare companies closest to Sun Pharmaceutical Industries by market cap are Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Apollo Hospitals Enterprise, Laurus Labs and Cipla.
Is Sun Pharmaceutical Industries a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sun Pharmaceutical Industries' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUNPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text